HOME >> BIOLOGY >> NEWS
Cold Virus With P53 Gene Tested To Combat Ovarian Cancer

DALLAS - October 28, 1998 - Researchers at UT Southwestern Medical Center at Dallas are using the p53 gene, inserted into an inactive common-cold virus, as a novel way to attack ovarian cancer in a patient.

Drs. Carolyn Muller and Robert Coleman, assistant professors of obstetrics and gynecology, said p53 is known as the housekeeper gene because it patrols for damaged cells, and if the cells cannot be repaired or are growing out of control and can't be contained, the p53 gene turns on its second line of defense: a built-in cell-death program, a process called apoptosis. The p53 mutations are the most common mutations in solid tumors and are found in 50 percent to 79 percent of ovarian cancers.

Muller said the normal p53 genes are replicated in the laboratory and inserted into adenoviruses, which act as carriers. During the treatment procedure, the patient's large amount of abdominal fluids, caused by the cancer, is withdrawn, and a therapeutic mixture of engineered p53 genes floating in saline is injected into the abdominal cavity. There the viral "geneboats" deliver the p53 gene to all cells. Once the gene is turned on in cancer cells, the invading "housekeeper" goes to work, recognizes the cancer cell's DNA damage and condemns it to death.

Muller and Coleman, who work in the Harold C. Simmons Comprehensive Cancer Center and the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, said that this trial will determine several things. They include the appropriate mixture of engineered viruses in the solution, the sequence of doses, the length of treatment and the manner in which the patient reacts to it. The first patient's treatments are occurring in three weekly visits with two-week intervals between them. Patients will continue treatments as long as a positive response occurs unless significant side effects develop. Fifteen to 18 patients are expected to be treated in this study.

Nancy Ruff, a 65-year-old wife, mother and grand
'"/>

Contact: Ann Harrell
ann.harrell@email.swmed.edu
214-648-3404
UT Southwestern Medical Center
28-Oct-1998


Page: 1 2

Related biology news :

1. Virus known for its photo ops makes its movie screen debut
2. Viruses clear bacterial contamination in chickens
3. Viruses may be environmentally friendly decontaminants
4. The Virus-Cancer Link: Examining the Role of Viruses in the Development of Cancer
5. Virus researchers close in on the secret life of DNA
6. Virus beats food bug
7. West Nile Virus cases analyzed for prevalence and symptoms
8. West Nile Virus can cause polio-like symptoms
9. Antibodies critical for fighting West Nile Virus infection
10. CDC Telebriefing: Smallpox educational activities and West Nile Virus update
11. West Nile Virus capsid protein causes encephalitic inflammation by triggering cell suicide

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cold Virus With Gene Tested Combat Ovarian Cancer

(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... available in pharmacies and health stores, phosphatidylserine is ... and soy. Proven to improve cognition and slow ... people experiencing memory impairment. Now a team headed ... of Tel Aviv University,s Department of Human ... supplement improves the functioning of genes involved in ...
(Date:5/21/2013)... Try staying fit in space, where living quarters are ... That,s the challenge a group of Michigan State University ... grant from NASA. Their goal is to keep astronauts ... could give astronauts the best exercise regimen there is, ... it, it isn,t going to help," said project leader ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... Miami, FL (PRWEB) May 21, 2013 ... and breakouts as contributor to acne. Recently physicians from ... effects of mental stress on the skin, and suggested ... to help reduce the chemicals produced from stress that ... aside from the negative feelings acne brings about, stress ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
Cached News: